|1.||Trias, Joaquim: 5 articles (01/2013 - 01/2009)|
|2.||Rosenson, Robert S: 4 articles (01/2014 - 02/2009)|
|3.||Fraser, Heather: 4 articles (01/2013 - 01/2009)|
|4.||Hislop, Colin: 3 articles (09/2010 - 01/2009)|
|5.||Murakami, Makoto: 2 articles (04/2015 - 03/2013)|
|6.||Gelb, Michael H: 2 articles (04/2015 - 11/2009)|
|7.||Koenig, Wolfgang: 2 articles (01/2014 - 09/2009)|
|8.||Kastelein, John J P: 2 articles (01/2014 - 04/2011)|
|9.||Minucci, Angelo: 2 articles (01/2013 - 05/2012)|
|10.||De Luca, Daniele: 2 articles (01/2013 - 05/2012)|
05/01/2012 - "Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. "
05/01/2012 - "The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. "
10/01/1999 - "Pretreatment with S-5920/LY315920Na diminished the OA-induced PLA(2) activity in the BALF and dose-dependently attenuated the previously described lung injury induced by OA, accompanied by protection against lung surfactant degradation and production of thromboxane A(2) (TXA(2)) and leukotriene B(4) (LTB(4)). "
05/01/2012 - "Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury."
04/01/2001 - "Treatment with S-5920/LY315920Na 1 hr after OA infusion, but not 2 hrs after infusion, significantly attenuated the lung injury, as estimated by hypoxemia, decreased lung compliance, pulmonary edema, and vascular permeability. "
|2.||Acute Lung Injury
01/01/2013 - "Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. "
04/01/2001 - "We attempted to determine whether group IIA secretory phospholipase A2 (sPLA2-IIA) blockade after the onset of lung injury exerted therapeutic efficacy in the treatment of oleic acid (OA)-induced acute lung injury by using S-5920/LY315920Na, a novel specific inhibitor of sPLA2-IIA, with special interest in the changes of lung surfactant. "
03/01/2003 - "However, prospectively planned secondary analyses suggested that treatment with LY315920Na/S-5920 was associated with an improvement in survival in patients treated within 18 hrs of the first sepsis-induced organ failure."
08/01/2005 - "In a previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated and appeared to improve survival in a subgroup of patients who received the drug within 24 hrs of first sepsis-induced organ failure. "
03/01/2003 - "The primary objectives of this study were to determine whether there was a dose-response relationship between two doses of LY315920Na/S-5920 compared with placebo in the reduction of 28-day all-cause mortality in patients with severe sepsis and to determine whether LY315920Na/S-5920 had an acceptable safety profile.(2) (2) (2) Multicenter, double-blind, placebo-controlled trial of two doses of LY315920Na/S-5920 in a parallel design. "
08/01/2005 - "Multicenter, double-blind, placebo-controlled, parallel-group clinical trial of LY315920NA/S-5920 in patients with severe sepsis. "
03/01/2003 - "Administration of LY315920Na/S-5920 had an acceptable safety profile in patients with severe sepsis. "
10/01/2004 - "We investigated the efficacy of a potent inhibitor of secretory phospholipase A2 (sPLA2), S-5920/LY315920Na, in an experimental model of acute pancreatitis in rats. "
10/01/2004 - "Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats."
|1.||Secretory Phospholipases A2
|2.||Group II Phospholipases A2
|3.||Oleic Acid (Oleate)
|4.||Lipase (Acid Lipase)
|6.||Aspartate Aminotransferases (Aspartate Transaminase)
|9.||1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)